eteplirsen

FDA preps for DMD drug generics as Sarepta has yet to finish its confirmatory trial
Endpoints
Sat, 11/26/22 - 07:15 pm
Sarepta Therapeutics
generics
Duchenne Muscular Dystrophy
FDA
eteplirsen
3 trends in biotech to watch in 2020
Stat
Mon, 12/30/19 - 10:34 am
IPOs
eteplirsen
CAR-T
gene therapy
cell therapy
biotech
Europe Advisory Panel Rejects Sarepta’s Duchenne Drug Once Again
Xconomy
Fri, 09/21/18 - 09:49 am
Europe
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
eteplirsen
Sarepta’s eteplirsen spurned as European regulators turn thumbs down on controversial Duchenne MD drug
Endpoints
Thu, 05/3/18 - 11:14 pm
Sarepta Therapeutics
Duchenne Muscular Dystrophy
eteplirsen
Exondys 51
CHMP
Europe
New docs spotlight the FDA’s failed attempt to get Sarepta’s flawed Duchenne study retracted
Endpoints
Tue, 08/22/17 - 06:40 pm
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
eteplirsen
Sarepta May Have More Upside After Sales Data
Seeking Alpha
Thu, 01/19/17 - 11:47 am
Sarepta
Duchenne Muscular Dystrophy
Exondys 51
eteplirsen
​Why not everyone is buying the market hype surrounding Sarepta’s Duchenne drug - Boston Business Journal
Bizjournals.com
Sun, 11/13/16 - 11:56 am
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 5
eteplirsen
FDA emails show how upset some officials were over the Sarepta approval
Stat/Pharmalot
Sat, 11/5/16 - 01:25 pm
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
eteplirsen
FDA’s controversial OK for eteplirsen spurs second thoughts for a rejected rival at BioMarin
Endpoints
Thu, 10/13/16 - 03:33 pm
FDA
eteplirsen
Duchenne Muscular Dystrophy
Biomarin
Sarepta Therapeutics
After Sarepta win, BioMarin appeals DMD patent ruling
BioPharma Dive
Fri, 09/23/16 - 09:35 am
Sarepta Therapeutics
Biomarin
patents
Duchenne Muscular Dystrophy
eteplirsen
Kyndrisa
FDA commissioner calls for Sarepta drug study to be retracted
Stat/Pharmalot
Thu, 09/22/16 - 12:18 pm
FDA
Sarepta Therapeutics
Robert Califf
Duchenne Muscular Dystrophy
eteplirsen
Sarepta's New Drug May Make It a Takeover
Investopedia
Wed, 09/21/16 - 10:50 pm
Sarepta Therapeutics
eteplirsen
Duchenne Muscular Dystrophy
M&A
Sarepta, Patients Win - But What Of Regulatory Oversight?
Seeking Alpha
Tue, 09/20/16 - 11:10 am
Sarepta Therapeutics
regulatory
Duchenne Muscular Dystrophy
FDA
eteplirsen
Sarepta to charge $300K for Duchenne drug. ‘We tried to be reasonable,’ CEO says
Stat/Pharmalot
Tue, 09/20/16 - 09:49 am
Sarepta Therapeutics
Duchenne Muscular Dystrophy
drug pricing
eteplirsen
Behind the Sarepta drug approval was intense FDA bickering
Stat/Pharmalot
Mon, 09/19/16 - 03:21 pm
Sarepta Therapeutics
FDA
Duchenne Muscular Dystrophy
eteplirsen
FDA approves Sarepta’s controversial drug for Duchenne muscular dystrophy
Stat
Mon, 09/19/16 - 10:07 am
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
eteplirsen
Sarepta Therapeutics: Wait, I Thought Turmoil at the FDA Was Good News?
Barron's
Thu, 09/15/16 - 07:16 pm
Sarepta Therapeutics
FDA
eteplirsen
Duchenne Muscular Dystrophy
Sarepta Drug Critic Departs FDA, Raising Hope for Approval
TheStreet.com
Wed, 09/14/16 - 09:43 am
Sarepta Therapeutics
FDA
eteplirsen
Duchenne Muscular Dystrophy
10 Must-Know Biotech Stock Events to Close Out 2016
TheStreet.com
Fri, 09/9/16 - 09:04 pm
biotech
Eli Lilly
solanezumab
Biogen
aducanumab
Kite Pharma
KTE-C19
Bluebird Bio
LentiGlobin
Sarepta Therapeutics
eteplirsen
Ophthotech
Fovista
Bristol-Myers Squibb
Opdvio
Acadia
Nuplazid
Celgene
GED-301
Gilead Sciences
M&A
3 Biotech Stocks With Explosive Upside Potential
Motley Fool
Wed, 08/24/16 - 10:53 am
Acadia
Nuplazid
Radius Health
abaloparatide-SC
Sarepta Therapeutics
eteplirsen

Pages